With the potential to transform treatment for severe viral infections, our pipeline sets us on a clear and focused path towards rapid clinical product development and commercialization.

RNA Viruses

To address a variety of infections caused by RNA viruses, we are advancing product candidates that directly inhibit viral replication by blocking the synthesis of viral RNA. Based on nucleotide prodrug platforms, these product candidates are designed to offer uniquely potent and safe antiviral therapies, as well as potential prophylaxis for several severe RNA virus infections.


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), colloquially known as the coronavirus, is a positive single-stranded RNA virus that causes the coronavirus disease 2019, known as COVID-19, a highly contagious acute respiratory illness with life-threatening risks for certain patients.

Learn More
Hepatitis C

A blood borne liver infection, where a substantial unmet medical need remains for rapidly curative safe oral therapy, for large populations of patients, including those with compensated and decompensated cirrhosis, HIV co-infection, and patients at increased risk for adverse events or drug interactions with protease inhibitor-based regimens.

Learn More

A common, often debilitating, mosquito borne infection annually affecting millions of people worldwide, where no approved pharmaceutical treatment is available.

Learn More
Respiratory Syncytial Virus (RSV)

A common lung and respiratory tract infection affecting young children and older adults, for which no approved viral-specific pharmaceutical treatment is available.

Learn More